Osteoporosis is a widespread bone metabolic disease characterized by reduced bone mass and bone microstructure deterioration. Ribonucleotide reductase M2 (RRM2) is a key enzyme in DNA synthesis and repair. The present study investigated the effect of RRM2 on osteogenesis of mouse embryo fibroblasts (MEFs) and its molecular mechanism. Bioinformatics analysis revealed that RRM2 expression was increased during osteogenesis of MEFs triggered by bone morphogenetic protein 9. Subsequently, MEFs were used as a mesenchymal stem cell model and osteogenic inducing medium was used to induce osteogenic differentiation. RRM2 protein expression was measured by western blotting during osteogenic differentiation induction of MEFs. RRM2 levels in MEFs were upregulated and downregulated by RRM2‑overexpressing recombinant adenovirus and small interfering RNA‑RRM2, respectively. Bone formation markers (RUNX family transcription factor 2, osterix, distal‑less homeobox 5, collagen type I α1 chain, osteopontin and osteocalcin) were detected by reverse transcription‑quantitative (RT‑q) PCR and alkaline phosphatase (ALP) and Alizarin Red S staining were examined. The protein expression levels of β‑catenin and the ratio of phosphorylated (p‑)GSK‑3β to GSK‑3β were detected by western blotting and the RNA expression of downstream related target genes (β‑catenin, axis inhibition protein 2 (AXIN2), transcription factor 7 like 2, lymphoid enhancer binding factor 1, c‑MYC and Cyclin D1) in the Wnt/β‑catenin signaling pathway was measured by RT‑qPCR. RRM2 protein expression increased as the osteogenic differentiation induction period was extended. RRM2 overexpression increased osteogenic marker RNA expression, ALP activity, bone mineralization, the protein expression levels of β‑catenin, the ratio of p‑GSK‑3β to GSK‑3β and the RNA expression of downstream related target genes in the Wnt/β‑catenin signaling pathway, whereas RRM2 knockdown had the opposite effect. The findings of the present study revealed that RRM2 overexpression enhanced osteogenic differentiation, while RRM2 knockdown reduced osteogenic differentiation. RRM2 may regulate osteogenic differentiation of MEFs via the canonical Wnt/β‑catenin signaling pathway, providing a possible therapeutic target for osteoporosis.

Related Articles